This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback
Trial record 3 of 6 for:    S0802

Biomarkers of Bone Resorption in Metastatic Prostate Cancer

This study has been completed.
Information provided by (Responsible Party):
University of Aberdeen Identifier:
First received: November 2, 2010
Last updated: November 4, 2015
Last verified: November 2015
Biomarkers of bone resorption will be measured in the blood of patients with bone metastases from prostate cancer during the course of their illness. Changes in these biomarkers will be correlated with the patient's treatment with antiandrogen therapy and bisphosphonates and the response and/or progression of their cancer. It is hoped that serial measurement of these biomarkers may allow therapeutic monitoring in the future with successful individualisation of bisphosphonate therapy for metastatic prostate cancer.

Metastatic Prostate Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Measurement of Biomarkers of Bone Resorption in Patients With Hormone Sensitive Bone Metastases From Prostate Cancer Treated With Antiandrogen Therapy and Bisphosphonates

Resource links provided by NLM:

Further study details as provided by University of Aberdeen:

Enrollment: 40
Study Start Date: September 2010
Study Completion Date: August 2014
Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Bone Metastases


Ages Eligible for Study:   40 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
men with hormone sensitive prostate cancer with bone metastases

Inclusion Criteria:

  • prostate cancer with bone metastases
  • hormone sensitive

Exclusion Criteria:

  • inadequate renal function
  • ongoing dental problems
  • previous bisphosphonate therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01233557

United Kingdom
Aberdeen Royal Infirmary
Aberdeen, United Kingdom, AB25 2ZN
Sponsors and Collaborators
University of Aberdeen
Principal Investigator: Donald Bissett, M.D. NHS Grampian
  More Information

Responsible Party: University of Aberdeen Identifier: NCT01233557     History of Changes
Other Study ID Numbers: 10/S0802/36
Study First Received: November 2, 2010
Last Updated: November 4, 2015

Additional relevant MeSH terms:
Prostatic Neoplasms
Bone Resorption
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Bone Diseases
Musculoskeletal Diseases processed this record on August 18, 2017